Noven Announces Presentation of Data from Libido Study

NOVEN ANNOUNCES PRESENTATION OF DATA ON EFFECT OF
TRANSDERMAL COMBINATION HRT ON MOOD AND LIBIDO OF POSTMENOPAUSAL WOMEN

Back

Preliminary Study Data Presented in Berlin at 10th World Congress on the Menopause

Miami, FL, June 11, 2002 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) announced today that preliminary clinical data examining the effects of transdermal combination hormone replacement therapy (HRT) on the mood and libido of postmenopausal women is being presented today at the 10th World Congress on the Menopause in Berlin, Germany.

The presentation is entitled "Serum Endocrine Markers and Psychosexual Mood in Postmenopausal Women: The Difference Between Transdermal and Oral HRT." The data is being presented by Subir Roy, M.D., principal investigator on the study and Professor of Obstetrics and Gynecology at the Keck School of Medicine at the University of Southern California (USC). Additional information on the study is available by contacting USC at 323-442-2830.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products, including the only combination HRT patch available in the United States. For additional information on Noven, visit http://www.noven.com.

Investor & Media Contact:
Joseph C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
(305) 253-1916

Back